JAN 04, 2021 7:40 AM PST

Good Results From Trial of CAR T Cell Therapy for Non-Hodgkin Lymphoma

WRITTEN BY: Carmen Leitch

Researchers have reported positive results from a phase 2 clinical trial of a CAR T cell therapy called axicabtagene ciloleucel (axi-cel); after the treatment, cancer cells were undetectable in almost 80 percent of study participants, who all had advanced non-Hodgkin lymphoma (NHL, also known as Non Hodgkin's lymphoma). The findings were reported by the Dana-Farber Cancer Institute at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

"We were very impressed with the magnitude of the responses, and also the durability," said the leader of the trial, Dana-Farber's Caron Jacobson, MD, MMSc, who presented the findings. "This treatment has meaningfully impacted high-risk patients with these diseases. I was also struck early on by how favorable the safety profile was compared to what we've been seeing in the fast-growing lymphomas."

NHL usually progresses slowly, but patients often relapse after the standard treatment is applied, indicating that new approaches need to be developed. This study suggested that axi-cel worked well for patients that had already relapsed or who had cancers that were resisting the effects of other drugs.

T cell therapy involves taking immune T cells that target disease from a patient, then genetically modifying them so that they are better at latching on to cancer cells and destroying them. This modification is the addition of a receptor on the T cell surface known as CAR (chimeric antigen receptor). Once these patient-specific CAR T cells have been created and expanded so there are many of them, they can be returned to the patient, where they are supposed to go on to kill cancer cells.

CAR has been remodeled and improved since it was first developed. But it still works to target a molecule on cancer cells called CD19. When originally tested as a treatment for relapsed or refractory large B-cell lymphoma, over half of the patients went into remission and though some neurological side effects were seen in about 22 percent of the 20 patients, this was a reduction from previous CAR T cell trials. There were also some side effects involving a severe release of inflammatory molecules called cytokines in about four of the 20 patients in the trial.

Modified from CDC/ Robert Denty / Photo Credit: James Gathany

Axi-cel was given to 146 patients with slow-growing types of non-Hodgkin cancer called follicular lymphoma or marginal zone lymphoma in the ZUMA-5 trial. All of the study volunteers had active cases of lymphoma even though they'd undergone multiple rounds of treatment.

There was a detectable cancer reduction in 92 percent of the trial participants after 17.5 months of the trial. Unfortunately, adverse side effects were also seen in nearly all the patients, some involving cytokines and some involving the neurological system.

Sources: AAAS/Eurekalert! via Dana-Farber Cancer Institute

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 19, 2020
Cardiology
Examining a Possible Link Between Atherosclerosis and Inflammation
NOV 19, 2020
Examining a Possible Link Between Atherosclerosis and Inflammation
The immune system’s primary duty is to protect the body from dangerous invaders. Many don’t know that it als ...
DEC 09, 2020
Genetics & Genomics
Weed-Killer Causes Epigenetic Changes That May Predict Disease Risk
DEC 09, 2020
Weed-Killer Causes Epigenetic Changes That May Predict Disease Risk
Glyphosate is a common weed-killing chemical used in agriculture, and it may be best known as the active ingredient in R ...
JAN 12, 2021
Cardiology
SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin
JAN 12, 2021
SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin
One of the biggest problems that come alongside diabetes is the increased risk of cardiovascular disease. Treatment of d ...
JAN 10, 2021
Microbiology
Some Bacteria Know the Time
JAN 10, 2021
Some Bacteria Know the Time
People, animals, and even plants are known to have biological clocks, and new work has revealed that free-living bacteri ...
JAN 16, 2021
Cell & Molecular Biology
Watching RNA Folding As Its Being Made
JAN 16, 2021
Watching RNA Folding As Its Being Made
Once thought of primarily as an intermediary between the coding portions of DNA and proteins, our understanding of RNA a ...
JAN 17, 2021
Cell & Molecular Biology
How a Nutrient Can Aid in Infection Prevention
JAN 17, 2021
How a Nutrient Can Aid in Infection Prevention
Antibiotic-resistant microbes are considered to be a serious threat to public health, one of many reasons why it's impor ...
Loading Comments...